FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136926> ?p ?o ?g. }

• W4324136926 endingPage "260" @default.
• W4324136926 startingPage "260" @default.
• W4324136926 abstract "260 Background: NGS to identify HRR mutations (mut) is indicated in advanced prostate cancer (aPC); samples for testing may be tissue or plasma. In a large real-world (RW) database, we determined concordance between plasma ctDNA and primary tumor tissue (PT) and/or metastatic tissue (MT) for BRCA1, BRCA2, and ATM mut in PC patients (pts) who received both LB and tissue NGS any time during standard of care (SOC) management. The study objective was to assess the utility of LB to detect actionable mut in these HRR genes and demonstrate the utility of combined LB and tissue testing. Methods: We examined de-identified data from pts who had NGS using both Tempus xF (105 genes-LB) and Tempus xT (648 genes-tissue) during SOC for aPC. Analyses included 1) PT and LB and 2) MT and LB. The results from the pts’ earliest PT or MT and earliest LB were used for paired analyses. The prevalence of a pathogenic/likely pathogenic germline and/or somatic mut in BRCA1, BRCA2, or ATM was reported as N (%), 95% CI. The sensitivity of the LB to identify observed HRR mut in tissue was also reported as N (%), 95% CI. Concordance between pairs was evaluated by Cohen’s kappa statistic with 95% CI. Results: HRR results are show for 1074 PC pts who had NGS performed on PT and LB and 451 PC pts with NGS on both MT and LB. In the PT and LB analysis, HRR mut were found in 6.2% (95% CI: 4.9%-7.9%) of LB and 8.8% (95% CI: 7.2%-11%) of PT. The sensitivity of LB to detect HRR mut in the PT was 53% (95% CI: 43%-64%). Cohen’s kappa statistic was 0.59, 95% CI=0.50-0.68, between PT and LB. In the MT and LB analysis, HRR mut were found in 10% (95% CI 7.8%-14%) of LB and 10% (7.6%-13%) of MT. The sensitivity of LB to detect HRR mut in the MT was 70% (95% CI: 54%-82%). Cohen’s kappa statistic was 0.65, 95% CI=0.54-0.77, between MT and LB. Conclusions: In this large RW dataset, plasma ctDNA-based analysis of BRCA1, BRCA2, and ATM mut showed greater concordance between LB and MT than LB and PT, and may be used as an initial tool for HRR mut detection. When LB results are negative, further exploration with tissue-based testing may identify HRR mut to guide clinical decisions. [Table: see text]" @default.
• W4324136926 created "2023-03-15" @default.
• W4324136926 creator A5005059266 @default.
• W4324136926 creator A5007315039 @default.
• W4324136926 creator A5011367118 @default.
• W4324136926 creator A5021900842 @default.
• W4324136926 creator A5044955842 @default.
• W4324136926 creator A5063271702 @default.
• W4324136926 creator A5079063325 @default.
• W4324136926 creator A5086664647 @default.
• W4324136926 date "2023-02-20" @default.
• W4324136926 modified "2023-09-25" @default.
• W4324136926 title "Homologous recombination repair (HRR) mutation concordance between liquid biopsy (LB) and tumor tissue by NGS in a real-world prostate cancer (PC) database." @default.
• W4324136926 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.260" @default.
• W4324136926 hasPublicationYear "2023" @default.
• W4324136926 type Work @default.
• W4324136926 citedByCount "0" @default.
• W4324136926 crossrefType "journal-article" @default.
• W4324136926 hasAuthorship W4324136926A5005059266 @default.
• W4324136926 hasAuthorship W4324136926A5007315039 @default.
• W4324136926 hasAuthorship W4324136926A5011367118 @default.
• W4324136926 hasAuthorship W4324136926A5021900842 @default.
• W4324136926 hasAuthorship W4324136926A5044955842 @default.
• W4324136926 hasAuthorship W4324136926A5063271702 @default.
• W4324136926 hasAuthorship W4324136926A5079063325 @default.
• W4324136926 hasAuthorship W4324136926A5086664647 @default.
• W4324136926 hasConcept C104317684 @default.
• W4324136926 hasConcept C109825262 @default.
• W4324136926 hasConcept C121608353 @default.
• W4324136926 hasConcept C126322002 @default.
• W4324136926 hasConcept C13514818 @default.
• W4324136926 hasConcept C142724271 @default.
• W4324136926 hasConcept C143998085 @default.
• W4324136926 hasConcept C160798450 @default.
• W4324136926 hasConcept C2780192828 @default.
• W4324136926 hasConcept C501734568 @default.
• W4324136926 hasConcept C54355233 @default.
• W4324136926 hasConcept C71924100 @default.
• W4324136926 hasConcept C86803240 @default.
• W4324136926 hasConceptScore W4324136926C104317684 @default.
• W4324136926 hasConceptScore W4324136926C109825262 @default.
• W4324136926 hasConceptScore W4324136926C121608353 @default.
• W4324136926 hasConceptScore W4324136926C126322002 @default.
• W4324136926 hasConceptScore W4324136926C13514818 @default.
• W4324136926 hasConceptScore W4324136926C142724271 @default.
• W4324136926 hasConceptScore W4324136926C143998085 @default.
• W4324136926 hasConceptScore W4324136926C160798450 @default.
• W4324136926 hasConceptScore W4324136926C2780192828 @default.
• W4324136926 hasConceptScore W4324136926C501734568 @default.
• W4324136926 hasConceptScore W4324136926C54355233 @default.
• W4324136926 hasConceptScore W4324136926C71924100 @default.
• W4324136926 hasConceptScore W4324136926C86803240 @default.
• W4324136926 hasIssue "6_suppl" @default.
• W4324136926 hasLocation W43241369261 @default.
• W4324136926 hasOpenAccess W4324136926 @default.
• W4324136926 hasPrimaryLocation W43241369261 @default.
• W4324136926 hasRelatedWork W2054415895 @default.
• W4324136926 hasRelatedWork W2890786570 @default.
• W4324136926 hasRelatedWork W2891719975 @default.
• W4324136926 hasRelatedWork W3126639524 @default.
• W4324136926 hasRelatedWork W3159671141 @default.
• W4324136926 hasRelatedWork W3203503196 @default.
• W4324136926 hasRelatedWork W4291209206 @default.
• W4324136926 hasRelatedWork W4320914613 @default.
• W4324136926 hasRelatedWork W4361284628 @default.
• W4324136926 hasRelatedWork W4377293822 @default.
• W4324136926 hasVolume "41" @default.
• W4324136926 isParatext "false" @default.
• W4324136926 isRetracted "false" @default.
• W4324136926 workType "article" @default.